Literature DB >> 9784452

Time trend analysis and variations in prescribing lipid lowering drugs in general practice.

C Baxter1, R Jones, L Corr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9784452      PMCID： PMC28697          DOI： 10.1136/bmj.317.7166.1134

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

Authors:  T J Bowker; T C Clayton; J Ingham; N R McLennan; H L Hobson; S D Pyke; B Schofield; D A Wood
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

2.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

3.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321
  3 in total
  22 in total

1.  Use of statins in general practices, 1996-8: cross sectional study.

Authors:  C Packham; J Pearson; J Robinson; D Gray
Journal:  BMJ       Date:  2000-06-10

2.  Did the major clinical trials of statins affect prescribing behaviour?

Authors:  M M Mamdani; J V Tu
Journal:  CMAJ       Date:  2001-06-12       Impact factor: 8.262

3.  A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care.

Authors:  John Kedward; Lorraine Dakin
Journal:  Br J Gen Pract       Date:  2003-09       Impact factor: 5.386

4.  Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.

Authors:  Zheng Zhou; Elham Rahme; Michal Abrahamowicz; Jack V Tu; Mark J Eisenberg; Karin Humphries; Peter C Austin; Louise Pilote
Journal:  CMAJ       Date:  2005-04-26       Impact factor: 8.262

5.  Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland.

Authors:  Päivi Ruokoniemi; Arja Helin-Salmivaara; Timo Klaukka; Pertti J Neuvonen; Risto Huupponen
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

6.  Assessing heart disease risk in primary care. Cholesterol lowering should be just one part of a multiple risk factor intervention.

Authors:  T Fahey
Journal:  BMJ       Date:  1998-10-24

7.  Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial.

Authors:  G Feder; C Griffiths; S Eldridge; M Spence
Journal:  BMJ       Date:  1999-06-05

8.  Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark.

Authors:  S Riahi; K Fonager; E Toft; L Hvilsted-Rasmussen; J Bendsen; S Paaske Johnsen; H T Sørensen
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

9.  Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.

Authors:  Chen-Chang Yang; Susan S Jick; Marcia A Testa
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

10.  Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England.

Authors:  P R Ward; P R Noyce; A S St Leger
Journal:  J Epidemiol Community Health       Date:  2004-02       Impact factor: 3.710
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.